Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | F2R | P25116 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 6/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085428 | 0.84 | KCNJ5 (0.55) | RORC | |
| SCHEMBL7088400 | 0.82 | NPC1 (0.58) | KCNK3KCNK9GRM4 | |
| SCHEMBL7223242 | 0.78 | ABCC9 (0.40) | — | |
| SCHEMBL7085218 | 0.78 | CTNNB1 (0.51) | PTGS1RORC | |
| SCHEMBL7091413 | 0.77 | NPC1 (0.48) | P2RX1 | |
| SCHEMBL27510728 | 0.77 | TNF (0.41) | RORC | |
| SCHEMBL7085359 | 0.77 | PIN1 (0.47) | — | |
| SCHEMBL7089037 | 0.76 | KMT2A (0.55) | RORC | |
| SCHEMBL28744461 | 0.76 | PTPRC (0.50) | KCNK3KCNK9PTPRCPTGS1F2R | |
| SCHEMBL8211752 | 0.75 | RAB9A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | MERCK PATENT GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| US-6559185-B2 | Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use | MERCK PATENT GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| US-20030069312-A1 | Antidiabetic agents | LARDY CLAUDE (FR) | 2003-04-10 | — | — | US | disclosed |
| CN-1257474-A | New nitromethylketone compounds, process for their preparation and compositions containing them | MERCK PATENT GMBH (DE) | 2000-06-21 | — | — | CN | disclosed |
| US-6043281-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0983226-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GmbH (DE) | 2000-03-08 | — | — | EP | disclosed |
| US-5932765-A | REDUCTASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT (DE) | 1999-08-03 | — | — | US | disclosed |
| WO-1998052906-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069312-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GPR119 | KCNK3 2755/4885KCNK9 3412/4885PTPRC 1254/4885 |
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | AKR1B1, AKR1A1, AKR1C1 | KCNK3 1348/4885KCNK9 1724/4885PTPRC 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.